$0.00
USD 0.00(0.00%)
1 month
Volume
Market Cap
52 Week
Prev. Close
About Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases and other disorders. The company was founded on May 31, 2012 and is headquartered in New York, NY.
Sector
Health Technology
CEO
Sergio Traversa
Industry
Pharmaceuticals: Major
Exchange
NASDAQ
Website
Top Stories
Coming soon.